Podokinesis in endothelial cell migration: role of nitric oxide.

Previously, we demonstrated the role of nitric oxide (NO) in transforming epithelial cells from a stationary to locomoting phenotype [E. Noiri, T. Peresleni, N. Srivastava, P. Weber, W. F. Bahou, N. Peunova, and M. S. Goligorsky. Am. J. Physiol. 270 ( Cell Physiol. 39): C794-C802, 1996] and its permissive function in endothelin-1-stimulated endothelial cell migration (E. Noiri, Y. Hu, W. F. Bahou, C. Keese, I. Giaever, and M. S. Goligorsky. J. Biol. Chem. 272: 1747-1753, 1997). In the present study, the role of functional NO synthase in executing the vascular endothelial growth factor (VEGF)-guided program of endothelial cell migration and angiogenesis was studied in two independent experimental settings. First, VEGF, shown to stimulate NO release from simian virus 40-immortalized microvascular endothelial cells, induced endothelial cell transwell migration, whereas N G-nitro-l-arginine methyl ester (l-NAME) or antisense oligonucleotides to endothelial NO synthase suppressed this effect of VEGF. Second, in a series of experiments on endothelial cell wound healing, the rate of VEGF-stimulated cell migration was significantly blunted by the inhibition of NO synthesis. To gain insight into the possible mode of NO action, we next addressed the possibility that NO modulates cell matrix adhesion by performing impedance analysis of endothelial cell monolayers subjected to NO. The data showed the presence of spontaneous fluctuations of the resistance in ostensibly stationary endothelial cells. Spontaneous oscillations were induced by NO, which also inhibited cell matrix adhesion. This process we propose to term "podokinesis" to emphasize a scalar form of micromotion that, in the presence of guidance cues, e.g., VEGF, is transformed to a vectorial movement. In conclusion, execution of the program for directional endothelial cell migration requires two coexisting messages: NO-induced podokinesis (scalar motion) and guidance cues, e.g., VEGF, which imparts a vectorial component to the movement. Such a requirement for the dual signaling may explain a mismatch in the demand and supply with newly formed vessels in different pathological states accompanied by the inhibition of NO synthase.

[1]  M. Goldberg,et al.  Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*) , 1995, The Journal of Biological Chemistry.

[2]  K. Jacobson,et al.  Forces exerted by locomoting cells. , 1994, Seminars in cell biology.

[3]  I. Giaever,et al.  Micromotion of mammalian cells measured electrically. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[5]  Y. Kaneda,et al.  Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  K. Alitalo,et al.  Endothelial receptor tyrosine kinases involved in angiogenesis , 1995, The Journal of cell biology.

[7]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[8]  S Amerini,et al.  Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. , 1994, The Journal of clinical investigation.

[9]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[10]  K. Ichimori,et al.  Practical nitric oxide measurement employing a nitric oxide‐selective electrode , 1994 .

[11]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[12]  H. Granger,et al.  Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. , 1996, The American journal of physiology.

[13]  G. Jennings,et al.  An energy dispersive x‐ray absorption spectroscopy beamline, X6A, at NSLS , 1994 .

[14]  N. Flavahan.  Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity. , 1992, Circulation.

[15]  M. Goligorsky,et al.  Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells. Receptor coupling to nitric oxide synthase. , 1994, The Journal of biological chemistry.

[16]  J. Liao,et al.  Oxidized Low-density Lipoprotein Decreases the Expression of Endothelial Nitric Oxide Synthase (*) , 1995, The Journal of Biological Chemistry.

[17]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[18]  P. Kubes,et al.  Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Liu,et al.  Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. , 1993, The American journal of physiology.

[20]  C. Lo,et al.  Monitoring motion of confluent cells in tissue culture. , 1993, Experimental cell research.

[21]  Von der Leyen.  Gene therapy inhibiting neointimal vascular lesion , 1995 .

[22]  A. Koch,et al.  Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Ivar Giaever,et al.  Permissive Role of Nitric Oxide in Endothelin-induced Migration of Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[24]  J. Loscalzo,et al.  Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. , 1995, The Journal of clinical investigation.

[25]  D. Gospodarowicz,et al.  Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[26]  P Rhodes,et al.  Roles of nitric oxide in tumor growth. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S J Singer,et al.  The directed migration of eukaryotic cells. , 1986, Annual review of cell biology.

[28]  A. Ullrich,et al.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.

[29]  A. M. Lefer,et al.  Decreased basal nitric oxide release in hypercholesterolemia increases neutrophil adherence to rabbit coronary artery endothelium. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[30]  L. Dubertret,et al.  Exogenous nitric oxide elicits chemotaxis of neutrophils in vitro , 1995, Journal of cellular physiology.

[31]  M. Goligorsky,et al.  Nitric oxide is necessary for a switch from stationary to locomoting phenotype in epithelial cells. , 1996, The American journal of physiology.

[32]  Y. Yamaguchi,et al.  Purification and biological characterization of epitaxin, a fibroblast-derived motility factor for epithelial cells. , 1994, The Journal of biological chemistry.

[33]  B. Tönshoff,et al.  Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. , 1994, Kidney international.